Scaanz LLC

I.  Introduction.

 

A Gateway to a Healthier Future! (www.scaanz.com)

 

Scaanz is transforming the healthcare landscape with its innovative and affordable AI-driven health screening service. This service is non-invasive and utilizes a subscription-based model, making advanced health technology accessible to everyone. With just your smartphone camera, you can detect common diseases early. Our state-of-the-art AI technology employs a highly sophisticated neural network, trained to analyze images with exceptional accuracy. Initially, Scaanz is targeting the detection and eradication of Malaria, and will subsequently expand to the early detection of Diabetes and animal testing. This breakthrough approach not only enhances disease prevention but also significantly reduces the burden on healthcare systems. With Scaanz, you hold the power to proactively safeguard your well-being with the ease of a smartphone selfie. Join us on this extraordinary health-tech voyage, where your health is our top priority.

 

·       Scaanz provides rapid and accurate malaria diagnosis, delivering results in just seconds, outperforming current Rapid Diagnostic Tests (RDTs) in time and accuracy. 

·       Unlike microscopy tests, which are highly accurate but limited to hospitals with trained technicians and specimen transport, Scaanz is scalable and can be administered virtually anywhere with minimal training.

·       Scaanz eliminates manufacturing and supply chain limitations commonly associated with existing malaria tests, ensuring a more accessible and readily available solution.

·       Scaanz offers an affordable alternative to other testing methods, making malaria diagnosis accessible to a broader population.

 

·       As affirmed by both the Health Ministers of Mali and Ghana, daily testing is deemed essential, and this demand cannot be met effectively through invasive RTDs and Microscopy testing methods.

III. Product validation

At present, the Scaanz AI is trained using one subset of the data, while a separate dataset is employed for validation. This approach ensures that the AI assesses patients who have not been previously encountered by the machine. Additional validation is to be carried out during the FDA approval process, where the AI would be tested on fresh data not yet seen by the machine. 

Currently the results are as follows:

 | Accuracy | 82%
 | Sensitivity | 87%
 | Specificity | 81%

This data will improve with additional testing data.

IV. Market Opportunity

 

Our initial focus on combatting malaria in Africa holds the potential to save millions of lives. Currently, more than 600,000 individuals succumb to this deadly disease each year. Alarmingly, a staggering 77% of these fatalities are innocent children under the age of 5. Our strategy places paramount importance on ensuring testing accessibility for this vulnerable age group through comprehensive parental education and training initiatives.

 

Upon obtaining certification from the Ghana Food and Drugs Authority (FDA), our initial deployment will commence in Ghana. Subsequently, we plan to expand our reach to encompass all fifteen member nations of the Economic Community of West African States (ECOWAS) in Q2 of 2025. The goal is to extend our life-saving impact to the entire African continent, which bears witness to 95% of all global malaria cases. We aim to achieve this ambitious objective by the conclusion of 2026.

 

To facilitate the widespread adoption of our innovative digital testing modality, we are committed to establishing strategic partnerships and securing additional certifications from reputable entities such as the World Health Organization. These partnerships, coupled with our collaboration with strong implementation partners, will serve as the catalysts driving the successful implementation of this groundbreaking initiative.

 

In the context of the malaria market in Ghana, an unprecedented opportunity emerges as Scaanz is poised to penetrate approximately 30 million mobile devices. This substantial reach is made possible through a government mandate championed by the President of Ghana, the communication minister and health minister, reflecting a clear commitment to advancing healthcare accessibility.

 

Furthermore, within Ghana's consumer landscape, approximately 34% of the population demonstrates the financial capacity to afford a Scaanz subscription independently. To extend this life-saving service to the remaining segments of the population, a collaborative effort is envisioned. This collective endeavor entails contributions from the private sector, non-governmental organizations (NGOs), government entities, and pharmaceutical companies, demonstrating a holistic approach to address healthcare challenges and maximize the impact of malaria diagnosis and prevention.

Survey of Target Market

Survey in Ghana - We conducted a survey in Ghana to find out if consumers would utilize Scaanz technology for their own use and the results were positive.  

While our initial focus lies in combatting malaria, we recognize the immense potential of our Scaanz AI platform to address a broader spectrum of diseases. Market research conducted by Grand View Research and Markets & Markets highlights the following promising opportunities:

·      Veterinary Diagnostic Market is currently $3.3 billion and expected to Reach $5.0 billion by 2029. Poised to grow at a CAGR of 7.1%

·      Diabetes Testing: This market, valued at $27.8 billion in 2020, is projected to grow at a CAGR of 4.4% from 2020 to 2025.

 

While our primary focus centers on eradicating malaria, these compelling opportunities underscore the potential for our Scaanz AI platform to revolutionize disease detection and diagnosis across diverse healthcare domains.

V. Team

KIRILL MOSTOV, PhD, Co-Founder, CEO

Founder & CEO of Kirsen Technologies and principal architect of Clevr’s precision navigation solutions. Technology lead for first autonomous vehicle on a US Highway (vehicle in Smithsonian). Founded and exited multiple companies. Assisted Steve Jobs on the navigation features of the initial iPhone. Author of 22 US and International Patents. PhD in Electrical Engineering and Computer Sciences, and a Master’s in Math, from UC Berkeley with emphasis on location-based services using AI, GPS, & other sensor fusion techniques.

 

Dan brings a distinguished track record of elevating brand equity and driving value, spanning from startups to Fortune 500 companies. Notably, he orchestrated the successful launch of the Carter-Thomason facial closure device, eventually acquired by Cooper Surgical. He spearheaded Cadence Design's achievement of selling the inaugural Bluetooth developer's kit to Phillips. He also introduced the highly prosperous Allon4 dental prosthetic procedure for Nobel Biocare a $100B market. Also, during his tenure as Senior VP of Sales and Marketing at AvaDent Digital Dental Solutions, Dan achieved a remarkable sales surge, exceeding 400% growth within a mere four years.

 

Currently serving as the Chairman and CEO of TimeX Capital since February 2023. He previously served as the Chairman of EMPEREAL ENERGY AND SERVICES for 12 years. Arun also served as the Founder Chairman/CEO and CFO of Empereal. He recently served as the Chief Financial Officer and Executive Advisor to the Board of SprintRay Inc. in Washington, D.C. 

 

Alexander Zemlyak has served as Senior Investment Manager at LETA Capital. He was responsible for deals sourcing and closing, portfolio management, content creation, networking, and fund promotion both in Israel, Silicon Valley, Europe and globally. While at LETA he closed 8 investment deals (incl. Novakid, Buddy.ai, Gaviti, Affise, Simbi, ShapesXR) Prior to LETA Alexander served as a Senior Advisor for EiM out of Singapore and London.

A 20-year veteran of artificial intelligence algorithm development. Pioneered use of deep learning neural nets in multiple industrial verticals. Cofounded two startups & helped raise 20M+ in grants and equity funding. PhD in Electrical Engineering and Computer Science from MIT.

10 Years as Co-Founder and Chief Operations Officer for EmailDirect.com which was acquired by J2 Global (JCOM). Led handoff and migration of SaaS customers to Campaigner.com. 3 Years as Co-Founder and CEO of iPressGo.com. Led successful transition of leadership for company before successfully exiting. Proven skills in SaaS product management, software design, graphic design, operations, omni- channel customer support solutions and online marketing.

Engineering lead: VP Engineering, eLutions Integrated Systems, VP Research Development, DCG Systems, Sr. Director Engineering, EFA Group, Credence Systems. Instrumental Director to Credence/LTX 2008 merger. PhD in Physics from University of California Berkeley.

CTO of Kirsen Technologies and principal architect of Kirsen Location tracking solutions. Author of US, International and Chinese patents. Masters in Microdevices and Technical Cybernetics from MIET University with extensive background in development of IOT platforms including integrated systems with numerous active clients and devices simultaneously transmitting high volumes of data.

VI. Favorable Environment

·      We have garnered significant political support from the Presidents of Ghana and Mali, underscoring our commitment to addressing healthcare challenges in the region.

·      Expedited FDA Approval: The Health Minister of Ghana has expedited the FDA approval process for Scaanz, paving the way for its swift deployment.

·      We are actively collaborating with the health ministers of Ghana and Mali to explore NIH grant opportunities, reinforcing our dedication to advancing healthcare solutions.

VII. Financial Projections

Our subscription based model has estimated 5-Year gross revenue in excess of $790M with net profit margins in excess of 39%

VIII.   Conclusion

 

In conclusion, Scaanz is poised to usher in a new era of healthcare through its innovative, on-demand health screening solution. Our initial focus on combatting malaria in Africa reflects our commitment to saving lives and improving healthcare accessibility. With rapid, accurate results obtained through a simple selfie, we have the potential to make a profound impact in the fight against this deadly disease.

 

Beyond malaria, our Scaanz AI platform opens doors to a myriad of future health testing opportunities for both humans and the animal kingdom. As we embark on this transformative journey, we invite you to join us in reshaping the landscape of healthcare. Together, we can make accurate, affordable, and accessible health screening a reality for millions of individuals and animals worldwide. With your support, Scaanz is not only changing lives but also setting new standards in disease detection and diagnosis.